sonelokimab

Home
Ligands
sonelokimab

GtoPdb Ligand ID: 10491

Synonyms: IL17-MS3086 | IL17MS3086 | SEQ ID 836 [WO2012156219A1]

Comment: Sonelokimab (IL17MS3086) is an anti-IL-17A/F single chain camelid nanobody [1]. The peptide sequence for proposed INN sonelokimab is a 100% match for SEQ ID 836 that is claimed in Merck/Ablynx patent WO2012156219A1. IL17MS3086 potently binds to both IL-17A and -F and prevents IL-17R pathway activation (e.g . IL-6 production), and was designed for anti-inflammatory potential. We provide the IL17MS3086 to sonelokimab association in good faith, and await formal disclosure.

References
1. Bruniquel D, Chavalet L, Chvatchko Y, Kilkman JA, Leger O, Proudfoot AEI, Rommelaere H, Saunders MJS, Union A, Vicari A. (2012) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same. Patent number: WO2012156219A1. Assignee: Ablynx Nv, Merck Patent Gmbh. Priority date: 05/05/2011. Publication date: 22/11/2012.

References

1. Bruniquel D, Chavalet L, Chvatchko Y, Kilkman JA, Leger O, Proudfoot AEI, Rommelaere H, Saunders MJS, Union A, Vicari A. (2012)
Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same.
Patent number: WO2012156219A1. Assignee: Ablynx Nv, Merck Patent Gmbh. Priority date: 05/05/2011. Publication date: 22/11/2012.